(Q37016086)

17 August 2017

1 reference

title

Antiangiogenic agents for the treatment of glioblastoma (English)

1 reference

17 August 2017

main subject

angiogenesis inhibitor

1 reference

5

Rakesh K Jain

1 reference

17 August 2017

3

Emmanuelle di Tomaso

1 reference

17 August 2017

6

Tracy T Batchelor

1 reference

17 August 2017

Elizabeth R Gerstner

1

1 reference

17 August 2017

Dan G Duda

series ordinal

2

1 reference

17 August 2017

Greg Sorensen

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1895-1908

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Mechanisms of angiogenesis in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Angiogenesis in malignant glioma--a target for antitumor therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Matrix metalloproteinases: biologic activity and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Integrin signaling and cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Requirement of vascular integrin alpha v beta 3 for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

A perivascular niche for brain tumor stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Development of matrix metalloproteinase inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Treatment of cerebral metastases from breast carcinoma with prednisolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Effect of bevacizumab on radiation necrosis of the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferation and migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1895

10.1517/13543784.16.12.1895

21 January 2018

Identifiers

DOI

1 reference

release_q57yhdoujzhpvaibnbuixg2uoe

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q57yhdoujzhpvaibnbuixg2uoe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference